Stocks of Gilead Sciences Inc. (NASDAQ:GILD) traded higher last session on Wall Street, down -1.22% to $74.24.
According to the data, Gilead Sciences Inc. (NASDAQ:GILD) has 30 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $116.00 and a low of $71.00, we find $90.00. Given the previous closing price of $75.16, this indicates a potential upside of 19.74 percent. GILD stock price is now -3.97% away from the 50-day moving average and -8.56% away from the 200-day moving average. The market capitalization of the company currently stands at $92.30B.
A total of 15 analysts have issued a hold rating and 13 have given it a buy rating. Brokers who have rated the stock have averaged $90.55 as their price target over the next twelve months.
With the price target of $71, HSBC Securities recently initiated with Reduce rating for Gilead Sciences Inc. (NASDAQ: GILD).
In other news, Dickinson Andrew D, Chief Financial Officer sold 5,000 shares of the company’s stock on Jul 20. The stock was sold for $400,000 at an average price of $80.00. Upon completion of the transaction, the Chief Financial Officer now directly owns 107,587 shares in the company, valued at $7.99 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 28, 10% Owner GILEAD SCIENCES, INC. bought 1,010,000 shares of the business’s stock. A total of $19,452,600 was incurred on buying the stock at an average price of $19.26. This leaves the insider owning 14,823,029 shares of the company worth $1.1 billion. Insiders disposed of 230,852 shares of company stock worth roughly $17.14 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GILD stock. A new stake in Gilead Sciences Inc. shares was purchased by UNISUPER MANAGEMENT PTY LTD during the first quarter worth $23,325,000. TWINBEECH CAPITAL LP invested $20,829,000 in shares of GILD during the first quarter. In the first quarter, EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in Gilead Sciences Inc. valued at approximately $20,734,000. GENUS CAPITAL MANAGEMENT INC. acquired a new stake in GILD for approximately $11,262,000. SIMPLEX TRADING, LLC purchased a new stake in GILD valued at around $9,081,000 in the second quarter. In total, there are 2,350 active investors with 83.00% ownership of the company’s stock.
During the past 12 months, Gilead Sciences Inc. has had a low of $61.44 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.19, a current ratio of 1.00, and a quick ratio of 0.90. According to the stock market information, the enterprise value for the company is $112.23B, which is based on a 17.08 price-to-earnings ratio, a 4.88 price-to-earnings-growth ratio, and a beta of 0.39. The fifty day moving average price for GILD is $77.26 and a two-hundred day moving average price translates $81.15 for the stock.
The latest earnings results from Gilead Sciences Inc. (NASDAQ: GILD) was released for Jun, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.34, missing analysts’ expectations of $1.64 by -0.3. This compares to $0.90 EPS in the same period last year. The net profit margin was 20.00% and return on equity was 26.00% for GILD. The company reported revenue of $6.6 billion for the quarter, compared to $6.26 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.42 percent. For the current quarter, analysts expect GILD to generate $6.8B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/28/2023. Investors who held shares on 09/15/2023 were paid a $0.75 dividend. On an annualized basis, this represents a $3.00 dividend and a 4.04% percent yield. There was an ex-dividend date of 09/14/2023 for this dividend. In terms of dividend payout ratio, GILD is presently at 67.60%.
Gilead Sciences Inc.(GILD) Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
